Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Commissioner Margaret Hamburg says Genentech has failed to identify a subpopulation of patients in whom the clinical benefits outweigh the risks. The company says it will not appeal the indication’s withdrawal but will pursue a new study in breast cancer.
You may also be interested in...
Vanda May Go Another Round With US FDA Over Hetlioz Jet Lag Indication
Agency offers Vanda chance to request a hearing over its plan to refuse to approve its supplemental new drug application. Such a hearing seems unlikely given FDA’s rejection of past requests and Vanda’s track record with the agency.
Makena Sponsor Covis Seeks To Use FDA Officials’ Words, Actions On Accelerated Approval Against CDER
Company cites comments by Oncology Center of Excellence Director Richard Pazdur and Office of Neuroscience Director Billy Dunn on reasons why confirmatory trials fail and the need for regulatory flexibility. Ironically, both senior officials have publicly extracted commitments from companies to withdraw products if postmarketing trials do not verify clinical benefit.
Accelerated Approval: Former ODAC Member Sekeres Reflects On Avastin Withdrawal
Leukemia specialist Mikkael Sekeres’ new book, “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust,” serves two purposes: a history of FDA oversight and regulation of drugs, as shaped by various public health crises and tragedies; and an insider's account of the June 2011 hearing on withdrawal of Avastin’s accelerated approval in breast cancer.